Axitinib suppliers

Axitinib

CAS:: 319460-85-0

MF:: C22H18N4OS

MW:: 386.47

SecurityInformation

Symbol(GHS) ：: GHS07,GHS09

Signal word ：: Warning

Hazard statements ：: H302-H400

Precautionary statements ：: P273-P301+P312+P330

Hazard Codes ：: Xn,N

Risk Statements ：: 22-50/53

Safety Statements ：: 60-61

RIDADR ：: UN 3077 9 / PGIII

WGK Germany ：: 3

HS Code ：: 29333990

Use：: In January 2012, the US FDA approved axitinib (also referred to as AG-013736) for the treatment of advanced renal cell carcinoma (RCC) for patients who have not responded to prior therapy. Axitinib is a pan VEGF inhibitor and functions by binding to the intracellular tyrosine kinase catalytic domain of VEGF leading to blockade of signaling through this angiogenic pathway. Axitinib is50–400 times more potent for VEGF (enzyme Ki and cellular IC50s for VEGF 1, 2, and 3 are ～0.1 nM) than first-generation inhibitors like sorafenib and sunitinib. Axitinib also inhibits c-Kit and PDGFR(α/β) with enzyme Ki's of ～2 nM and was selective when tested against a broad panel of other protein kinases. Axitinib was discovered by a structure-based drug design approach and binds to the kinase domain of VEGF in a DFG-out conformation. Axitinib blocks VEGF-2 phosphorylation up to 7 h postdose in vivo and inhibits endothelial cell proliferation in xenograft tumors implanted in mice. Synthetic routes to axitinib employing a Migita coupling to form the diaryl sulfide and a Heck reaction to install the 2-styrylpyridine moiety have been reported.

More▼

You can find Axitinib suppliers, manufacturers, and distributors from countries such as CHINA, United States and the India here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.

Zison Pharmaceutical (Shandong) Co., Ltd.